Leveraging Hypomethylating Agents for Better MDS Therapy
Purpose of Review
Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed.
Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings.
Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.
KeywordsMyelodysplastic syndrome Acute myeloid leukemia Hypomethylating agents Isocitrate dehydrogenase Immunotherapy Pevonedistat
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.Sekeres MA, Cutler C (2018) How we treat higher-risk myelodysplastic syndromes 123:829–837.Google Scholar
- 2.Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.CrossRefGoogle Scholar
- 7.•Swords RT, Watts J, Erba HP, et al. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 2017;7:1–4 The results of this study merited the study of pevonedistat in combination with other active agents, including HMAs.CrossRefGoogle Scholar
- 9.Smith PG, Traore T, Grossman S, Narayanan U, Carew JS, Lublinksky A, et al. Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models. Blood. 2011;118:578–LP-578.Google Scholar
- 11.•Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–17 Demonstrated that venetoclax was biologically active in patients with AML, and suggested that priming was needed with HMAs and other low-dose chemotherapy combinations.CrossRefGoogle Scholar
- 13.DiNardo CD, Pollyea DA, Jonas BA, et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2017;130:2628 LP-2628.Google Scholar
- 17.Rausch CR, DiNardo CD, Kadia T, et al. Results of off-label venetoclax use in combination with low-intensity chemotherapy in patients with relapsed and refractory myeloid malignancies. Blood. 2017;130:1356 LP-1356.Google Scholar
- 19.Quintás-Cardama A, FPS S, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2011;25:226–35.Google Scholar
- 22.Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. J Clin Oncol. 2014;32:1242–8.CrossRefGoogle Scholar
- 27.Silverman LR, Verma A, Odchimar-Reissig R, Cozza A, Najfeld V, Licht JD, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consorti. J Clin Oncol. 2008;26:7000.CrossRefGoogle Scholar
- 28.Luger SM, O’Connell CL, Klimek V, Cooper MA, Besa EC, Rossetti JM, et al. A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). J Clin Oncol. 2013;31:7116.Google Scholar
- 29.Garcia-Manero G, Berdeja JG, Komrokji RS, Essell J, Lyons RM, Maris M, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911 LP-911.Google Scholar
- 31.Garcia Manero G, Atallah E, Khaled SK, et al. A phase 2 study of pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) not eligible for induction chemotherapy: response and long-term survival benefit. Blood. 2016;128:100 LP-100.Google Scholar
- 32.DiNardo CD, De Botton S, Stein EM, et al. Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: results of a phase 1 dose escalation and expansion study. Blood. 2017;130:725 LP-725.Google Scholar
- 33.Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS). Blood. 2016;128:343 LP-343.Google Scholar
- 35.•DiNardo CD, Stein EM, de Botton S, et al (2018) Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med NEJMoa1716984. Will change the standard of care for IDH1-mutant myeloid malignancies. Google Scholar
- 36.DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with Azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130:–639 LP-639.Google Scholar
- 39.Garcia-Manero G, Tallman MS, Martinelli G, Ribrag V, Yang H, Balakumaran A, et al. Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of Hypomethylating agent treatment. Blood. 2016;128:345 LP-345.Google Scholar
- 41.Garcia-Manero G, Daver NG, Montalban-Bravo G, et al. A phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS)1. (2016) A Phase II Study. Blood. 2016;128:344 LP-344.Google Scholar
- 42.Daver N, Garcia-Manero G, Basu S, et al. Nivolumab (Nivo) with azacytidine (AZA) in patients (pts) with relapsed acute myeloid leukemia (AML) or frontline elderly AML. Blood. 2017;130:1345 LP-1345.Google Scholar
- 45.Wang Z, Dove P, Shamas-Din A, et al. The highly potent bromodomain (BRD) inhibitor FV-281 displays preclinical efficacy in acute myeloid leukemia (AML). Blood. 2015;126:1364 LP-1364.Google Scholar
- 46.Forero-Torres A, Rosen S, Smith DC, et al. Preliminary results from an ongoing phase 1/2 study of INCB057643, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced malignancies. Blood. 2017;130:4048 LP-4048.Google Scholar